Targeting host deubiquitinases for broad spectrum anti-infective therapy
靶向宿主去泛素酶进行广谱抗感染治疗
基本信息
- 批准号:8389503
- 负责人:
- 金额:$ 19.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAnimal ModelAnti-Infective AgentsAntiviral AgentsBacteriaBacteriologyBiochemistryBiological AssayCantaloupesCategoriesCellsChemicalsCommunicable DiseasesDataDevelopmentDiagnosisDisease OutbreaksDrug KineticsDrug resistanceEarly treatmentEconomicsEncephalomyocarditis virusEnzymesFutureGastroenteritisGoalsHumanIn VitroInfectionInfection preventionInfectious AgentInjection of therapeutic agentInvestigational New Drug ApplicationLa Crosse virusLeadLinkListeriaListeria monocytogenesLiver MicrosomesMediatingMicrobeModelingMolecular WeightMorbidity - disease rateMusNorovirusOrganismParasitesPharmaceutical ChemistryPharmacologyPhasePositioning AttributeProteinsProteomicsPublic HealthResearchRoleSalmonella entericaSeriesSindbis VirusSolubilityStructure-Activity RelationshipTestingTherapeuticToxic effectToxoplasma gondiiUbiquitinUbiquitinationUnited StatesVaccinesViral GastroenteritisVirusWarWaterage groupanalogantimicrobialbasecytotoxicitydrug developmentdrug resistant bacteriaeffective therapyfoodbornefoodborne illnessfoodborne infectionfoodborne pathogenin vivoinhibitor/antagonistmethicillin resistant Staphylococcus aureusmicrobialmortalitynovelnovel therapeuticspathogenpolypeptidepre-clinicalprogramssmall moleculetherapeutic targetvirology
项目摘要
DESCRIPTION (provided by applicant): There is an urgent need for new therapeutics to effectively target drug-resistant microbes and pathogens that currently have no treatment options. Noroviruses cause an estimated 23 million infections and over half of all food-borne gastroenteritis outbreaks in the US every year yet no antivirals or vaccines exist to treat or prevent infections. Listeria monocytogenes is another food-borne pathogen with a 20 - 25% fatality rate, responsible for recent cantaloupe-associated food-borne infection outbreaks. There is a compelling rationale for developing broad-spectrum therapeutics for early and effective treatment of infectious diseases. One approach towards that goal is development of "anti-infective" compounds that target host-encoded proteins critical during pathogen infection. Ubiquitin is a eukaryotic low molecular weight polypeptide that acts as a post-translational regulatory switch when covalently linked to target proteins. This application provides preliminary data showing a small molecule, WP1130 (WP) and related compounds have anti-infective activity against different classes of pathogens, including: category B bacteria (MRSA, Listeria monocytogenes, Salmonella enterica serovar Typhimurium); viruses (murine and human norovirus, encephalomyocarditis virus, Sindbis virus, La Crosse virus); and an apicomplexan parasite (Toxoplasma gondii). WP inhibits a subset of host cell deubiquitinases (DUBs), causing accumulation of ubiquitinated proteins. Pathogens outside the host are not affected. Studies using WP analogs provide vital clues for development of novel therapeutics that may effectively control pathogens by interfering with key host and microbe interactions. Ubiquitination and deubiquination of host targets have critical roles in many microbial infections.
We hypothesize that WP can limit infection by selectively inhibiting DUBs exploited by microbial pathogens. We will use murine norovirus and L. monocytogenes and established small animal models of infection to define DUB targets that mediate the anti-infective effects of WP. Our goal is to select lead compound to be utilized in an investigational new drug (IND) application. We propose the following specific aims: (1) Determine target DUBs of WP that mediate anti-infective activity, (2) Test a SAR series of WP in vitro to identify lead compounds, and (3) Test lead compounds for in vivo efficacy. This application proposes to develop broad-spectrum anti-infective therapeutics that have efficacy against many pathogens including multiple category B agents.
PUBLIC HEALTH RELEVANCE: Infectious agents are a major cause of morbidity and mortality in the United States today. The emergence of drug resistant organisms is a major public health concern. We have identified a novel compound with anti-infective activity against many microbial pathogens that include: drug-resistant bacteria; viruses; and parasites. Further study of this compound could lead to development of therapeutics that target critical cellular enzymes used by pathogens.
描述(由申请人提供):迫切需要新的治疗方法来有效靶向目前没有治疗选择的耐药微生物和病原体。诺如病毒每年在美国造成约2300万例感染,占所有食源性胃肠炎爆发的一半以上,但目前还没有抗病毒药物或疫苗来治疗或预防感染。单核细胞增生李斯特菌是另一种食源性病原体,致死率为20 - 25%,是最近香瓜相关食源性感染爆发的原因。有一个令人信服的理由,发展广谱疗法的早期和有效的治疗传染病。实现该目标的一种方法是开发“抗感染”化合物,其靶向病原体感染期间关键的宿主编码蛋白质。 泛素是一种真核生物低分子量多肽,当与靶蛋白共价连接时充当翻译后调节开关。 本申请提供了显示小分子WP 1130(WP)和相关化合物对不同种类的病原体具有抗感染活性的初步数据,所述病原体包括:B类细菌(MRSA、单核细胞增生李斯特菌、鼠伤寒沙门氏菌血清型);病毒(鼠和人诺如病毒、脑心肌炎病毒、辛德毕斯病毒、拉克罗斯病毒);和顶复门寄生虫(刚地弓形虫)。 WP抑制宿主细胞去泛素化酶(DUB)的一个子集,导致泛素化蛋白的积累。 宿主外的病原体不受影响。 使用WP类似物的研究为开发新的疗法提供了重要线索,这些疗法可以通过干扰关键的宿主和微生物相互作用来有效地控制病原体。宿主靶标的泛素化和去泛素化在许多微生物感染中具有关键作用。
我们假设WP可以通过选择性抑制微生物病原体利用的DUB来限制感染。我们将使用鼠诺如病毒和L。单核细胞增多症和建立感染的小动物模型,以确定介导WP抗感染作用的DUB靶标。我们的目标是选择用于研究性新药(IND)申请的先导化合物。我们提出了以下具体目标:(1)确定介导抗感染活性的WP的靶DUB,(2)体外测试SAR系列WP以鉴定先导化合物,以及(3)测试先导化合物的体内功效。本申请提出开发广谱抗感染治疗剂,其对包括多种B类试剂的许多病原体具有功效。
公共卫生相关性:传染性病原体是当今美国发病率和死亡率的主要原因。 抗药性微生物的出现是一个重大的公共卫生问题。我们已经确定了一种新的化合物,对许多微生物病原体具有抗感染活性,包括:耐药细菌;病毒;和寄生虫。对这种化合物的进一步研究可能会导致开发针对病原体使用的关键细胞酶的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mary O'Riordan其他文献
Mary O'Riordan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mary O'Riordan', 18)}}的其他基金
Mitochondrial stress shapes host responses to bacterial infection
线粒体应激塑造宿主对细菌感染的反应
- 批准号:
10317161 - 财政年份:2021
- 资助金额:
$ 19.44万 - 项目类别:
Mitochondrial stress shapes host responses to bacterial infection
线粒体应激塑造宿主对细菌感染的反应
- 批准号:
10413242 - 财政年份:2021
- 资助金额:
$ 19.44万 - 项目类别:
Mitochondrial stress shapes host responses to bacterial infection
线粒体应激塑造宿主对细菌感染的反应
- 批准号:
10616749 - 财政年份:2021
- 资助金额:
$ 19.44万 - 项目类别:
Mechanisms of host defense against membrane damage by pore-forming toxins
宿主防御成孔毒素膜损伤的机制
- 批准号:
8699346 - 财政年份:2013
- 资助金额:
$ 19.44万 - 项目类别:
Mobilization of lysosome anti-microbial defenses by the unfolded protein response
通过未折叠的蛋白质反应动员溶酶体抗微生物防御
- 批准号:
8519298 - 财政年份:2012
- 资助金额:
$ 19.44万 - 项目类别:
Targeting host deubiquitinases for broad spectrum anti-infective therapy
靶向宿主去泛素酶进行广谱抗感染治疗
- 批准号:
8854184 - 财政年份:2012
- 资助金额:
$ 19.44万 - 项目类别:
Mobilization of lysosome anti-microbial defenses by the unfolded protein response
通过未折叠的蛋白质反应动员溶酶体抗微生物防御
- 批准号:
8364443 - 财政年份:2012
- 资助金额:
$ 19.44万 - 项目类别:
Targeting host deubiquitinases for broad spectrum anti-infective therapy
靶向宿主去泛素酶进行广谱抗感染治疗
- 批准号:
8485542 - 财政年份:2012
- 资助金额:
$ 19.44万 - 项目类别:
Targeting host deubiquitinases for broad spectrum anti-infective therapy
靶向宿主去泛素酶进行广谱抗感染治疗
- 批准号:
8891354 - 财政年份:2012
- 资助金额:
$ 19.44万 - 项目类别:
Use of host derived lipoate by Listeria monocytogenes
单核细胞增生李斯特菌使用宿主来源的硫辛酸
- 批准号:
7050534 - 财政年份:2005
- 资助金额:
$ 19.44万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 19.44万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 19.44万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 19.44万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 19.44万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 19.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 19.44万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 19.44万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 19.44万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 19.44万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 19.44万 - 项目类别:
Grant-in-Aid for Early-Career Scientists